论文部分内容阅读
目的:探讨格列齐特结合舒洛地特对2型糖尿病早期肾病患者血管内皮细胞功能的影响。方法:选取四川省遂宁市中心医院内分泌代谢病科2012年1月至2014年7月收治的2型糖尿病早期肾病患者120例,随机分为观察组和对照组,每组60例。对照组患者采用格列齐特治疗,观察组采取格列齐特结合舒洛地特治疗,观察两组患者治疗前、后内皮依赖性血管舒张功能(FMD)、非内皮依赖性血管舒张功能(NMD)以及循环内皮祖细胞(EPC)数目的变化。结果:(1)两组治疗后FMD、NMD、循环EPC数均显著优于治疗前(P<0.05)。(2)治疗后观察组FMD、NMD、循环EPC改善情况显著优于对照组(P<0.05)。结论:格列齐特结合舒洛地特能明显改善2型糖尿病早期肾病患者血管内皮功能,值得在临床上推广应用。
Objective: To investigate the effect of gliclazide combined with sulodentia on the function of vascular endothelial cells in type 2 diabetic patients with early nephropathy. Methods: One hundred and twenty patients with type 2 diabetes mellitus with early nephropathy admitted from January 2012 to July 2014 in the Department of Endocrine and Metabolic Diseases of Suining Central Hospital of Sichuan Province were randomly divided into observation group and control group with 60 cases in each group. The patients in the control group were treated with gliclazide, the observation group was treated with gliclazide combined with sulodexide, and the endothelium-dependent vasodilation (FMD) and non-endothelium-dependent vasodilatation NMD) and circulating endothelial progenitor cells (EPCs). Results: (1) After treatment, the number of FMD, NMD and circulating EPC were significantly better than those before treatment (P <0.05). (2) After treatment, the improvement of FMD, NMD and circulating EPC in the observation group was significantly better than that in the control group (P <0.05). Conclusion: Gliclazide combined with sulodentia can significantly improve endothelial function in patients with early stage nephropathy of type 2 diabetes, which is worth popularizing in clinic.